Hemophilia: Concizumab, a New Treatment Option? Hemophilia: Concizumab, a New Treatment Option?
The results are from the prospective, multicenter, phase 3 explorer7 trial, involving 133 patients, including 80 with hemophilia A and 53 had hemophilia B.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 31, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Concizumab Prophylaxis Reduced Bleeding Rates in Hemophilia
(MedPage Today) -- Compared with on-demand treatment, prophylaxis with concizumab -- designed to achieve hemostasis in all hemophilia types -- reduced annualized bleeding rates among patients who have hemophilia A or B with inhibitors, the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 30, 2023 Category: Hematology Source Type: news
Is Pfizer Stock A Buy Or A Sell With Covid-Era Growth In The Rearview?
stock has tumbled this year as demand for Covid products wanes and amid a fresh challenge in the obesity treatment space. During the second quarter, Pfizer's sales plummeted by half and missed forecasts. Adjusted earnings also tumbled, but beat expectations by a penny. Excluding the impact of…#pfizer #novonordisk #nvo #elililly #lly #fda #hemophilia #rsv #sgen #nurtec (Source: Reuters: Health)
Source: Reuters: Health - August 24, 2023 Category: Consumer Health News Source Type: news
Blood-inquiry victim from Ipswich fears compensation let down
Haemophiliac Alan Burgess has survived 40 years with HIV and hepatitis C since being infected. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - July 28, 2023 Category: Consumer Health News Source Type: news
Down More Than 40%: Analysts Say Buy These 2 Beaten-Down Stocks Before They Rebound
Reverse psychology can be considered a desired quality in the stock market. It is only natural to gravitate toward the leaders in any field, and an investor’s urge to hop on the latest surging stock in search of those sweet gains is understandable. However, anyone familiar with the ins and outs of…#tipranks #strongbuys #hemophilia #huntington #hemgenix #australian #csl #phase12 #amt130 #josephschwartz (Source: Reuters: Health)
Source: Reuters: Health - July 28, 2023 Category: Consumer Health News Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease 5%, driven by lower...
Source: Roche Investor Update - July 27, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions ’ base business; Group sales and profit reflect declining demand for COVID-19 products
Basel, 27 July 2023Excluding COVID-19 products,Groupsales increase strongly by 8%1at constant exchange rates (CER)In line with the expected declining demand for COVID-19 products,Groupsales decrease 2% (-8% in Swiss francs)Pharmaceuticals Division sales grow strongly by 8% due to continued high demand for newer medicines; new eye medicine Vabysmo is the strongest growth driverDiagnostics Division ’s base businesscontinues its good growth momentum with an increase of 6%, while total divisional sales are 23% lower due to exceptionally high demand for COVID-19 tests in the first half of 2022Core earnings per share decrease ...
Source: Roche Media News - July 27, 2023 Category: Pharmaceuticals Source Type: news
America will struggle to pay for ultra-expensive gene therapies
T is familiar, the liquid inside could be water—but the price tag is a little more unusual. A shot of Zolgensma, a gene therapy for spinal-muscular atrophy, comes to $2.1m. It is one of a new generation of ultra-expensive medicines. Treatments for beta-thalassemia and haemophilia, two blood…#zolgensma #haemophilia #vertex #medicaid #michaelkleinrock #franciscollins #innovationcentre #zandyforbes #meirax #hepatitis (Source: Reuters: Health)
Source: Reuters: Health - July 22, 2023 Category: Consumer Health News Source Type: news
‘Hunting for Growth’: Goldman Sachs Says These 2 Stocks Could Rally up to 85% From Current Levels
It’s no secret that the stock market has rallied this year, with year-to-date gains near 17% on the S&P 500 and 35% on the NASDAQ. There’s also talk that this rally could turn into a true bull market, putting investors in an upbeat mood and providing a welcome counterpoint to the widespread belief…#goldmansachs #deepmehta #goldman #tipranks #biomarin #vimizin #morquioa #maroteauxlamy #roctavian #hemophilia (Source: Reuters: Health)
Source: Reuters: Health - July 17, 2023 Category: Consumer Health News Source Type: news
Cheaper, more accessible cell, gene therapies? Nobel winner's task force points the way.
As more gene and cell therapies work their way through clinical trials — and some, like BioMarin's hemophilia A gene therapy costing millions of dollars — now is the time to look at new ways to develop, manufacturing and pay for those treatments, a task force says. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 7, 2023 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
What is gene therapy, and how does it work?
The Food and Drug Administration on Thursday approved a treatment that uses gene therapy to treat severe hemophilia A, a rare and sometimes fatal blood disorder. The new drug, Roctavian, could save people with the severe form of the disease from a lifetime of frequent injections. The drug’s maker…#roctavian #hemophilia #fda #hemgenix (Source: Reuters: Health)
Source: Reuters: Health - July 1, 2023 Category: Consumer Health News Source Type: news
FDA Approves First Gene Therapy for Severe Hemophilia A, Roctavian
FRIDAY, June 30, 2023 -- The U.S. Food and Drug Administration on Thursday approved a costly single-dose gene therapy for patients with severe hemophilia A. The treatment, Roctavian (valoctocogene roxaparvovec), will cost $2.9 million for a single... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 30, 2023 Category: General Medicine Source Type: news
FDA Approves First Gene Therapy for Severe Hemophilia A
FRIDAY, June 30, 2023 -- The U.S. Food and Drug Administration on Thursday approved a costly single-dose gene therapy for patients with severe hemophilia A, a life-threatening hereditary bleeding disorder.
The treatment is not cheap: Roctavian will... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 30, 2023 Category: General Medicine Source Type: news
FDA Approves First Gene Therapy for Hemophilia A FDA Approves First Gene Therapy for Hemophilia A
Most patients benefit from valoctocogene roxaparvovec for at least 2 years, but it ' s not known how long the effect lasts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 30, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Gives Nod to Gene Therapy for Hemophilia A
(MedPage Today) -- The FDA approved valoctocogene roxaparvovec (Roctavian) as the first gene therapy for the treatment of adults with severe hemophilia A, drug developer Biomarin announced on Thursday.
Patients with severe disease are eligible... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 30, 2023 Category: Hematology Source Type: news
